<?xml version="1.0" encoding="UTF-8"?>
<p>Originally developed for Ebola, this drug was the most obvious fit for SARS‐CoV‐2019 as it has already been tried out for ssRNA viruses like SARS and MERS.
 <xref rid="rmv2113-bib-0031" ref-type="ref">
  <sup>31</sup>
 </xref> Remdesivir is a prodrug whose phosphoramide is cleaved off to leave the active compound GS‐44‐1524 with a 
 <inline-formula>5
  <sup>′</sup>
 </inline-formula>OH. The active compound is processed by the RNA polymerase and gets incorporated into viral RNA. This leads to RNA termination and inhibition of viral replication. Five clinical trials of this drug are underway including two open‐label trials sponsored by Gilead, two phase‐III trials at China‐Japan Friendship Hospital in Hubei, and one adaptive‐design Phase II trial by NIH in Nebraska. Unfortunately, Remdesivir is commercially unavailable. Remdesivir has been used for one of the earliest patients of COVID‐19 in the United States on the basis of “compassionate use”.
 <xref rid="rmv2113-bib-0032" ref-type="ref">32</xref>, 
 <xref rid="rmv2113-bib-0033" ref-type="ref">33</xref>
</p>
